Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Blue light and ultraviolet radiation" are not molecules or receptors but rather forms of electromagnetic radiation within specific wavelength ranges. **Blue light** typically refers to visible wavelengths between approximately 400–500 nm. **Ultraviolet (UV) radiation** is non-visible electromagnetic energy subdivided into UV-A (315–400 nm), UV-B (280–315 nm), and UV-C (<280 nm). These types of radiation act as environmental signals that are detected by specialized photoreceptor proteins in living organisms. In plants and animals, the biological effects of blue/UV light are mediated by dedicated photoreceptors such as cryptochromes and phototropins. Cryptochromes absorb both blue and some ultraviolet wavelengths; they play key roles in regulating circadian rhythms in animals[3], controlling growth responses in plants[1][2], mediating stress responses[1], and influencing developmental processes like flowering time[3]. In bacteria, similar flavin-based receptors exist for sensing these wavelengths[1]. Ultraviolet radiation can also directly cause DNA damage—especially at shorter wavelengths—leading to mutations that underlie diseases such as skin cancer. While "blue light/UV radiation" itself is not a therapeutic target or molecular entity suitable for drug targeting, the downstream signaling pathways activated by their respective photoreceptors may be considered targets for intervention. Because "blue light/UV radiation" does not refer to a single molecule or receptor but rather physical phenomena detected by various molecular sensors across species, it is not appropriate to classify it as a canonical therapeutic target. The correct approach would be to specify individual photoreceptor proteins such as "Cryptochrome 1," "Phototropin," or others depending on context[6][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Blue light and ultraviolet radiation.